Chemistry:CUMYL-4CN-BINACA

From HandWiki
Revision as of 07:36, 8 February 2024 by JMinHep (talk | contribs) (over-write)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
CUMYL-4CN-BINACA
CUMYL-4CN-BINACA.svg
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC22H24N4O
Molar mass360.461 g·mol−1
3D model (JSmol)

CUMYL-4CN-BINACA (also known as CUMYL-CYBINACA or SGT-78) is an indazole-3-carboxamide based synthetic cannabinoid that has been sold online as a designer drug.[2][3][4][5][6][7] It is a potent agonist for cannabinoid receptors CB1 and CB2, with in vitro EC50 values of 0.58 nM and 6.12 nM, respectively.[8] In mice, CUMYL-4CN-BINACA produces hypothermic and pro-convulsant effects via the CB1 receptor,[8] and anecdotal reports suggest it has an active dose of around 0.1 mg in humans.[9]

CUMYL-4CN-BINACA is metabolized to produce cyanide, raising concerns about liver toxicity.[7] There is one reported case of hyperthermia, rhabdomyolysis, and kidney failure associated with its use.[10]

See also

References

  1. ↑ "Substance Details CUMYL-4CN-BINACA". https://www.unodc.org/LSS/Substance/Details/c9a6b008-085a-4c8c-960a-ae1c3200ae25. 
  2. ↑ "4-cyano CUMYL-BUTINACA". Cayman Chemical. https://www.caymanchem.com/product/20194. 
  3. ↑ "Identification of the Synthetic Cannabinoid 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in Plant Material and Quantification in Post-Mortem Blood Samples". Journal of Analytical Toxicology 41 (9): 720–728. November 2017. doi:10.1002/dta.2248. PMID 28977413. 
  4. ↑ "In vitro metabolism of the synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA". Drug Testing and Analysis 10 (1): 148–157. January 2018. doi:10.1002/dta.2298. PMID 28885775. 
  5. ↑ "Structural characterization of the new synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA". Forensic Science International 281: 98–105. December 2017. doi:10.1016/j.forsciint.2017.10.020. PMID 29125990. 
  6. ↑ "Identification of the synthetic cannabinoid N-(2-phenyl-propan-2-yl)-1-(4-cyanobutyl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in a herbal mixture product". Forensic Toxicology 36 (1): 192–199. January 2018. doi:10.1007/s11419-017-0372-y. ISSN 1860-8965. 
  7. ↑ 7.0 7.1 "Metabolism study for CUMYL-4CN-BINACA in human hepatocytes and authentic urine specimens: Free cyanide is formed during the main metabolic pathway". Drug Testing and Analysis 10 (8): 1270–1279. March 2018. doi:10.1002/dta.2373. PMID 29577658. 
  8. ↑ 8.0 8.1 "CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist". Frontiers in Pharmacology 10: 595. 2019. doi:10.3389/fphar.2019.00595. PMID 31191320. 
  9. ↑ "EMCDDA–Europol Joint Report on a new psychoactive substance: 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide (CUMYL-4CN-BINACA)". http://www.emcdda.europa.eu/publications/joint-reports/cumyl-4cn-binaca_en. 
  10. ↑ "A novel synthetic cannabinoid (Cumyl-4-cyano-BINACA) resulting in hyperthermia, rhabdomyolysis, and renal failure in a 29-year-old patient: it's not meningitis". Clinical Toxicology 57 (6): 421–422. June 2019. doi:10.1080/15563650.2018.1534241. PMID 30442067. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:CUMYL-4CN-BINACA&oldid=3421040"